NCT05659381 2026-04-16
HOTT
GOG Foundation
Phase 3 Recruiting
Clinical Trials
30 trialsNCT06824467 2026-04-16
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07214779 2026-04-16
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
NCT07318558 2026-04-16
TroFuse-021
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT04878094 2026-04-09
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT07225270 2026-04-08
RAINFOL-04
Genmab
Phase 3 Recruiting
NCT06580314 2026-03-24
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT07213804 2026-03-20
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT04789694 2026-03-19
PHOCUS
Charles University, Czech Republic
Phase 3 Recruiting
NCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06819007 2026-03-05
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT05445778 2026-02-23
GLORIOSA
AbbVie
Phase 3 Recruiting
NCT05827523 2026-02-13
FOCUS / KOV-04
National Cancer Center, Korea
Phase 3 Recruiting
NCT06963268 2025-12-19
SENTOV II
Instituto de Investigacion Sanitaria La Fe
Phase 3 Recruiting
NCT06855069 2025-12-17
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06476184 2025-12-05
SALVOVAR
ARCAGY/ GINECO GROUP
Phase 3 Recruiting
NCT06817161 2025-10-07
ESTANVO
Centre Francois Baclesse
Phase 3 Recruiting
NCT05804370 2025-10-01
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp
Phase 3 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT05796973 2025-06-27
MOVES
Tampere University Hospital
Phase 3 Recruiting
NCT06954584 2025-06-24
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital
Phase 3 Recruiting
NCT06828354 2025-03-24
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT04921527 2024-10-18
CHIPRO
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT06394492 2024-08-09
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT02429687 2023-04-25
MOGCT-01
Shandong University
Phase 3 Recruiting
NCT02429700 2023-04-25
SCST-01
Shandong University
Phase 3 Recruiting
NCT05255471 2023-03-24
MITO 35B
National Cancer Institute, Naples
Phase 3 Recruiting
NCT04520074 2022-07-27
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Fudan University
Phase 3 Recruiting